Crossman AR - Search Results

1

Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.

Segovia G, Mora F, Crossman AR, Brotchie JM. Segovia G, et al. Among authors: crossman ar. Mov Disord. 2003 Feb;18(2):138-49. doi: 10.1002/mds.10312. Mov Disord. 2003. PMID: 12539206

2

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Fox SH, et al. Mov Disord. 2002 Nov;17(6):1180-7. doi: 10.1002/mds.10289. Mov Disord. 2002. PMID: 12465055

3

Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.

Fox S, Silverdale M, Kellett M, Davies R, Steiger M, Fletcher N, Crossman A, Brotchie J. Fox S, et al. Mov Disord. 2004 May;19(5):554-60. doi: 10.1002/mds.10693. Mov Disord. 2004. PMID: 15133820 Clinical Trial.

4

Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.

Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM. Fox SH, et al. Among authors: crossman ar. Mov Disord. 2002 Jan;17(1):145-9. doi: 10.1002/mds.1280. Mov Disord. 2002. PMID: 11835452 Clinical Trial.

5

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM. Savola JM, et al. Among authors: crossman ar. Mov Disord. 2003 Aug;18(8):872-83. doi: 10.1002/mds.10464. Mov Disord. 2003. PMID: 12889076

6

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.

Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Hill MP, et al. Among authors: crossman ar. Mov Disord. 2003 Nov;18(11):1301-5. doi: 10.1002/mds.10542. Mov Disord. 2003. PMID: 14639671

7

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.

Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ. Hill MP, et al. Among authors: crossman ar. Mov Disord. 2006 Dec;21(12):2090-5. doi: 10.1002/mds.21106. Mov Disord. 2006. PMID: 16991143

8

Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate.

Brotchie JM, Mitchell IJ, Sambrook MA, Crossman AR. Brotchie JM, et al. Among authors: crossman ar. Mov Disord. 1991;6(2):133-8. doi: 10.1002/mds.870060208. Mov Disord. 1991. PMID: 1647492

9

The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.

Maneuf YP, Crossman AR, Brotchie JM. Maneuf YP, et al. Among authors: crossman ar. Exp Neurol. 1997 Nov;148(1):265-70. doi: 10.1006/exnr.1997.6645. Exp Neurol. 1997. PMID: 9398468

10

Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism.

Hughes NR, McKnight AT, Woodruff GN, Hill MP, Crossman AR, Brotchie JM. Hughes NR, et al. Among authors: crossman ar. Mov Disord. 1998 Mar;13(2):228-33. doi: 10.1002/mds.870130206. Mov Disord. 1998. PMID: 9539334

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

165 results

Search Page

Filters